CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg)

This 9mg blend combines CJC-1295 (Mod GRF 1-29) 3mg, Ipamorelin 3mg, and GHRP-2 3mg in a single vial, synthesized and lyophilized in the USA.

Each vial of CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg) contains a pre-weighed ratio of CJC-1295 3mg, Ipamorelin 3mg, GHRP-2 3mg in a single lyophilized cake, simplifying multi-peptide research protocols.

Work with CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg) typically combines receptor-binding assays with LC-MS identity confirmation for batch consistency.

CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg) is studied within growth-hormone research for its influence on the somatotropic axis in experimental protocols.

Investigations of CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg) commonly measure secretagogue activity and downstream signaling markers in controlled cell models.

Each vial contains lyophilized peptide at the labeled quantity, and wholesale orders are packed in boxes of ten vials at a single per-vial price.

Quality assurance: every batch is purified by reversed-phase high-performance liquid chromatography and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request. Store lyophilized vials at -20°C, protected from light and moisture; reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles. For in-vitro laboratory research use only — not for human or veterinary use.

Research & Literature

The following peer-reviewed studies and reference documents are commonly consulted by researchers working with CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg). Summaries are provided for orientation only and reflect the cited sources.

Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults^[1] — This study assessed the growth hormone and IGF-I responses to a single injection of the long-acting GHRH analog CJC-1295 in healthy adults. The authors examined the duration and magnitude of hormonal elevation following administration. The findings indicated that CJC-1295 produces prolonged stimulation of the GH-IGF-I axis, providing reference for the GHRH analog family to which Mod GRF 1-29 belongs. (The Journal of Clinical Endocrinology & Metabolism 2006)

Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog^[2] — This study examined whether continuous stimulation by the long-acting GHRH analog CJC-1295 alters the pulsatile pattern of growth hormone secretion. The authors reported that GH pulsatility was preserved while trough GH and IGF-I levels were raised. The findings suggested that GHRH-class peptides amplify GH output without disrupting its physiological pulsatile rhythm. (The Journal of Clinical Endocrinology & Metabolism 2006)

Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats^[3] — This study tested whether the growth-hormone-releasing peptide ipamorelin could stimulate longitudinal bone growth in rats. The authors examined the effects of ipamorelin administration on bone growth and related IGF-1 responses. The results suggested that ipamorelin promotes skeletal growth through stimulation of the GH-IGF-1 axis, supporting its role in this blend. (Growth Hormone & IGF Research 1999)

Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption^[4] — This study evaluated the pharmacokinetics of ipamorelin and other peptidyl growth hormone secretagogues, with particular attention to nasal absorption. The authors compared systemic exposure after different routes of administration. The findings indicated that ipamorelin has favorable absorption characteristics among the GHRP-class peptides. (Xenobiotica 1999)

Sustained Elevation of Pulsatile Growth Hormone (GH) Secretion and Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-3 (IGFBP-3), and IGFBP-5 Concentrations during 30-Day Continuous Subcutaneous Infusion of GH-Releasing Peptide-2 in Older Men and Women^[5] — This clinical study evaluated the effects of a 30-day continuous subcutaneous infusion of GH-releasing peptide-2 (GHRP-2) on the growth hormone and IGF axis in older men and women. The authors reported sustained elevations in pulsatile GH secretion and in IGF-I, IGFBP-3, and IGFBP-5 concentrations over the infusion period. The findings indicated that GHRP-2 can maintain enhanced GH output in an older population. (The Journal of Clinical Endocrinology & Metabolism 2004)

Development of growth hormone secretagogues^[6] — This review summarized the discovery and development of growth hormone secretagogues, including the peptide GHRP-2 and related ghrelin receptor ligands. The author traced how these compounds were identified and characterized as stimulators of endogenous GH release. The review provided context for the research use of GHRP-class peptides such as GHRP-2. (Endocrine Reviews 2005)

References

1. Teichman SL, et al.. "Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults." The Journal of Clinical Endocrinology & Metabolism. 2006. academic.oup.com/jcem/article-pdf/91/3/799/10779632/jcem0799.p…
2. Ionescu M, Frohman LA. "Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog." The Journal of Clinical Endocrinology & Metabolism. 2006. academic.oup.com/jcem/article-pdf/91/12/4792/9059878/jcem4792.…
3. Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. "Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats." Growth Hormone & IGF Research. 1999. pubmed.ncbi.nlm.nih.gov/10373343/
4. Johansen PB, Hansen KT, Andersen JV, Johansen NL. "Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption." Xenobiotica. 1999. pubmed.ncbi.nlm.nih.gov/9879640/
5. Bowers CY, et al.. "Sustained Elevation of Pulsatile Growth Hormone (GH) Secretion and Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-3 (IGFBP-3), and IGFBP-5 Concentrations during 30-Day Continuous Subcutaneous Infusion of GH-Releasing Peptide-2 in Older Men and Women." The Journal of Clinical Endocrinology & Metabolism. 2004. academic.oup.com/jcem/article-pdf/89/5/2290/10743682/jcem2290.…
6. Smith RG. "Development of growth hormone secretagogues." Endocrine Reviews. 2005. pubmed.ncbi.nlm.nih.gov/15814848/

All products are supplied as lyophilized powder for in-vitro laboratory research use only and are not for human or veterinary use.